Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

A Randomized, Open, Parallel Phase I Clinical Study on the Comparison of Pharmacokinetics Characteristics of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.

This study includes screening and treatment and follow-up periods.

Inclusion Criteria:

• Have the ability to understand the study.
• Voluntarily participate in the study and sign the ICF.
• 18 years ≤ age ≤ 65 years, male and female.
• Willing to take effective contraceptive measures during the study period.

Exclusion Criteria:

• Plan to receive any major surgery during the study period.
• With malignant tumors within 5 years before screening.
• Positive results of alcohol breath test or urine drug abuse screening during screening period.
• Any reason that the investigator believes that will prevent the subject from participating in the study.